IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading cause of kidney failure. Multiple new therapies are now being evaluated in randomized clinical trials globally. However, most individual trials are not powered to assess treatment effects in key patient subgroups or reliably evaluate effects on clinical kidney outcomes. IgAN varies considerably in its clinical presentation, rate of progression, and response to therapy, making it critical to understand how treatment effects differ across patients - yet individual trials are rarely designed or powered to address this. There is therefore a pressing need for coordinated international collaboration to deliver reliable evidence on the efficacy and safety of emerging therapies across the full range of patients living with IgAN.
 
CLARITY-IgAN is an academically initiated and led Consortium that aims to address this need through high-quality collaborative two-stage meta-analyses of data from major randomized controlled trials in IgAN. The Consortium aims to generate reliable estimates of the effects of various therapeutic classes on kidney, quality-of-life, and safety outcomes; understand how treatment effects vary across demographic, clinical, and histopathologic subgroups; better understand variations in the natural history of IgAN and longitudinal trajectories of proteinuria and eGFR; and develop and validate novel endpoints to enable more efficient future trials.
 
Together, these efforts aim to inform clinical practice guidelines, support regulatory science, and ultimately improve care for people living with IgAN worldwide.